Logo image of ANAB

ANAPTYSBIO INC (ANAB) Stock Fundamental Analysis

NASDAQ:ANAB - US0327241065 - Common Stock

20 USD
-0.13 (-0.65%)
Last: 8/29/2025, 9:48:05 AM
Fundamental Rating

2

Overall ANAB gets a fundamental rating of 2 out of 10. We evaluated ANAB against 547 industry peers in the Biotechnology industry. ANAB has a bad profitability rating. Also its financial health evaluation is rather negative. ANAB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ANAB had negative earnings in the past year.
ANAB had a negative operating cash flow in the past year.
In the past 5 years ANAB always reported negative net income.
In the past 5 years ANAB always reported negative operating cash flow.
ANAB Yearly Net Income VS EBIT VS OCF VS FCFANAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of ANAB (-39.55%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -39.55%
ROE N/A
ROIC N/A
ROA(3y)-29.09%
ROA(5y)-20.21%
ROE(3y)-146.58%
ROE(5y)-92.2%
ROIC(3y)N/A
ROIC(5y)N/A
ANAB Yearly ROA, ROE, ROICANAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANAB Yearly Profit, Operating, Gross MarginsANAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

ANAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ANAB has more shares outstanding
ANAB has more shares outstanding than it did 5 years ago.
ANAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANAB Yearly Shares OutstandingANAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ANAB Yearly Total Debt VS Total AssetsANAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

ANAB has an Altman-Z score of -2.17. This is a bad value and indicates that ANAB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ANAB (-2.17) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.17
ROIC/WACCN/A
WACC9.7%
ANAB Yearly LT Debt VS Equity VS FCFANAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 8.22 indicates that ANAB has no problem at all paying its short term obligations.
The Current ratio of ANAB (8.22) is better than 74.77% of its industry peers.
A Quick Ratio of 8.22 indicates that ANAB has no problem at all paying its short term obligations.
ANAB has a Quick ratio of 8.22. This is in the better half of the industry: ANAB outperforms 75.14% of its industry peers.
Industry RankSector Rank
Current Ratio 8.22
Quick Ratio 8.22
ANAB Yearly Current Assets VS Current LiabilitesANAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.45% over the past year.
Looking at the last year, ANAB shows a very strong growth in Revenue. The Revenue has grown by 304.15%.
ANAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 62.73% yearly.
EPS 1Y (TTM)29.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.64%
Revenue 1Y (TTM)304.15%
Revenue growth 3Y13.05%
Revenue growth 5Y62.73%
Sales Q2Q%102.93%

3.2 Future

ANAB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.56% yearly.
The Revenue is expected to grow by 30.98% on average over the next years. This is a very strong growth
EPS Next Y11.29%
EPS Next 2Y3.66%
EPS Next 3Y-2.14%
EPS Next 5Y0.56%
Revenue Next Year79.78%
Revenue Next 2Y39.57%
Revenue Next 3Y31.33%
Revenue Next 5Y30.98%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ANAB Yearly Revenue VS EstimatesANAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
ANAB Yearly EPS VS EstimatesANAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANAB Price Earnings VS Forward Price EarningsANAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANAB Per share dataANAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A cheap valuation may be justified as ANAB's earnings are expected to decrease with -2.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.66%
EPS Next 3Y-2.14%

More info and screens

0

5. Dividend

5.1 Amount

ANAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANAPTYSBIO INC

NASDAQ:ANAB (8/29/2025, 9:48:05 AM)

20

-0.13 (-0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners134.21%
Inst Owner Change-9.02%
Ins Owners2.1%
Ins Owner Change0.59%
Market Cap560.00M
Analysts84.44
Price Target47.53 (137.65%)
Short Float %34.32%
Short Ratio18.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.33%
Min EPS beat(2)-0.12%
Max EPS beat(2)14.78%
EPS beat(4)3
Avg EPS beat(4)25.8%
Min EPS beat(4)-0.12%
Max EPS beat(4)56.4%
EPS beat(8)5
Avg EPS beat(8)7.08%
EPS beat(12)7
Avg EPS beat(12)-2.75%
EPS beat(16)8
Avg EPS beat(16)-8.84%
Revenue beat(2)2
Avg Revenue beat(2)83.6%
Min Revenue beat(2)78.26%
Max Revenue beat(2)88.94%
Revenue beat(4)4
Avg Revenue beat(4)234.89%
Min Revenue beat(4)78.26%
Max Revenue beat(4)444.15%
Revenue beat(8)7
Avg Revenue beat(8)161.39%
Revenue beat(12)8
Avg Revenue beat(12)95.07%
Revenue beat(16)9
Avg Revenue beat(16)68.3%
PT rev (1m)9.39%
PT rev (3m)24.6%
EPS NQ rev (1m)8.75%
EPS NQ rev (3m)-1.45%
EPS NY rev (1m)14.56%
EPS NY rev (3m)13%
Revenue NQ rev (1m)34.26%
Revenue NQ rev (3m)120.09%
Revenue NY rev (1m)51.55%
Revenue NY rev (3m)81.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.55
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.48
EYN/A
EPS(NY)-4.82
Fwd EYN/A
FCF(TTM)-4.57
FCFYN/A
OCF(TTM)-4.56
OCFYN/A
SpS4.4
BVpS-1.6
TBVpS-1.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.09%
ROA(5y)-20.21%
ROE(3y)-146.58%
ROE(5y)-92.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.47%
Cap/Sales 0.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.22
Quick Ratio 8.22
Altman-Z -2.17
F-Score5
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)78.6%
Cap/Depr(5y)111.71%
Cap/Sales(3y)2.86%
Cap/Sales(5y)2.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.64%
EPS Next Y11.29%
EPS Next 2Y3.66%
EPS Next 3Y-2.14%
EPS Next 5Y0.56%
Revenue 1Y (TTM)304.15%
Revenue growth 3Y13.05%
Revenue growth 5Y62.73%
Sales Q2Q%102.93%
Revenue Next Year79.78%
Revenue Next 2Y39.57%
Revenue Next 3Y31.33%
Revenue Next 5Y30.98%
EBIT growth 1Y44.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.59%
EBIT Next 3Y6.65%
EBIT Next 5YN/A
FCF growth 1Y-62.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.87%
OCF growth 3YN/A
OCF growth 5YN/A